Insight Molecular Diagnostics Inc. (NasdaqCM: IMDX)
Health Care · Biotechnology · US
$3.17
-5.93% today · -13.6% 1Y
Insight Molecular Diagnostics Inc. (NasdaqCM: IMDX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $110.28M and employs 57 people.
Over the last twelve months the share price has lost 13.6%, trading between 2.42 and 8.51.
Tweenvest scores Insight Molecular Diagnostics Inc. across four factors: quality 30/100, value 34/100, growth 100/100. Its strongest factor is growth.
IMDX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $110.28M
- Revenue (TTM)
- $1.67M
- P/E
- —
- EPS
- -1.46
- Dividend yield
- —
- Beta (5Y)
- 1.80
- 52-week high
- $8.51
- 52-week low
- $2.42
- Avg volume (3M)
- —
- Shares outstanding
- 32.72M
- Employees
- 57
- Next earnings
- —
About Insight Molecular Diagnostics Inc.
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
- ISIN
- US68235C2061
- Founded
- 2009
- Listed since
- Dec 30, 2015
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Unicycive Therapeutics, Inc.NasdaqCM: UNCY | $114.49M | $4.05 | -1.46% |
| Inovio Pharmaceuticals, Inc.NasdaqCM: INO | $114.25M | $1.11 | -3.91% |
| Tonix Pharmaceuticals Holding Corp.NasdaqGS: TNXP | $113.88M | $6.64 | -9.04% |
| Hamlet BioPharma AB (publ)XSAT: HAMLET B | $113.40M | Skr6.08 | +1.50% |
| PDS Biotechnology CorporationNasdaqCM: PDSB | $110.16M | $1.52 | +10.14% |
| Conexeu Sciences Inc.NasdaqCM: CNXU | $109.72M | $3.77 | -3.08% |
| Great Novel Therapeutics Biotech & MedicalsTPEX: 7427 | $109.39M | NT$66.10 | -5.97% |
| Pharmosa Biopharm Inc.TPEX: 6875 | $109.08M | NT$27.00 | -9.70% |
Figures last refreshed Oct 11, 2026.